Tissue distribution and deposition of clofazimine in mice following oral administration with or without isoniazid

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 7, 2007, Pages 472-474

  Venkatesan, Krishnamurthy ^a   Deo, Nirmala ^a   Gupta, Umesh Dutt ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

CAS 2030 63 9; CAS 54 85 3; Clofazimine, combination with isoniazid, deposition, distribution, tissue; Isoniazid, combination with clofazimine; Leprostatics; Tuberculostatics

Indexed keywords

CLOFAZIMINE; ISONIAZID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TISSUE LEVEL; MOUSE; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION;

EID: 34547748924     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296634     Document Type: Article

References (18)

1. Browne S G, Hogerzeil L M. "B 663" in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev. 1962; 33:6-10.
2. Holdiness M R. Clinical pharmacokinetics of clofazimine - A review. Clin Pharmacokinet. 1989;16:74-85.
3. Venkatesan K. Clinical pharmacokinetic considerations in the treatment of leprosy patients. Clin Pharmacokinet. 1989;16:365-386.
4. O'Connor R, O'Sullivan J F, O'Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev. 1995;27:591-61.
5. Reddy V M, O'Sullivan J F, Gangadharam P R J. Antimycobactrial activities of riminophenazines. J Antimicrob Chemother. 1999;43:615-623.
6. Nix D E, Adam R D, Auclair B, Krueger T S, Godo P G, Peloquin C A. Pharmacokinetics and relative availability of clofazimine in relation to food, orange juice and antacid. Tuberculois (Edin). 2004;84:365-373.
7. Vischer W A. The experimental properties of G30 320 (B 663) - a new antileprotic agent. Lepr Rev. 1969;40:107-110.
8. Yawalkar S J, Vischer W. Lamprene (Clofazimine) in leprosy. Basic information. Lepr Rev. 1979;50:135-144.
9. Levy L. Pharmacologic studies of clofazimine. Am J Trop Med Hyg. 1974;23:1097-1109.
10. Mansfield R E. Tissue concentrations of clofazimine (B 663) in man. Am J Trop Med Hyg. 1974;23:1116-1119.
11. Desikan K V, Balakrishnan S. Tissue levels of clofazimine in a case of leprosy. Lepr Rev. 1976;47:107-114.
12. Jadhav M V, Sathe A G, Deore S S, Patil P G, Joshi N G. Tissue concentration, systemic distribution and toxicity of clofazimine- an autopsy study. Indian J Pathol Microbiol, 2004;47:281-283.
13. Venkatesan K, Bharadwaj V P, Ramu G, Desikan K V. A study of drug interactions in leprosy. Lepr India. 1980;52: 229-235.
14. Chang Y T. Effects of B663, a rimino compound of phenazine series in murine leprosy. In: Sylvester JC, ed. Antimicrobial Agents and Chemotherapy. Ann Arbor, Michigan: American Society for Microbiology; 1962. p 294-307.
15. Barry V C, Buggle J, Byrne M L, Conalty M L, Winder F. Absorption, distribution and retention of rimino compounds in the experimental animals. Ir J Med Sci. 1960;410:345-362.
16. Lanyi Z, Dubois JP. Determination of clofazimine in human plasma by thin layer chromatography. J Chromatogr. 1982;232:219-223.
17. Mamidi N V S R, Rajasekhar A, Prabhakar M C, Krishna D R. Tissue distribution and deposition of clofazimine in rat following subchronic treatment with or without rifampicin. Arzneimittel-Forschung (Drug Research). 1995;45:1028-1031.
18. McDougall A C, Jones R L. Intra-neural ceroid-like pigment following treatment of lepromatous leprosy with clofazimine (B 663, Lamprene). J Neurol Neurosurg Psychiat. 1981;44:116-120.